Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Public ClinicalTrials.gov record NCT00636168. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma
Study identification
- NCT ID
- NCT00636168
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,211 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2008
- Primary completion
- Jul 25, 2013
- Completion
- Nov 25, 2018
- Last update posted
- Dec 16, 2019
2008 – 2018
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic & Research Institute | Los Angeles | California | 90025 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| North. Cal. Melanoma Center-St. Mary's Medical Center | San Francisco | California | 94117 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| Boca Raton Comprehensive Cancer Center | Boca Raton | Florida | 33428 | — |
| H Lee Moffitt Cancer Cnt And Res Inst | Tampa | Florida | 33612 | — |
| Oncology Specialists, S.C. | Park Ridge | Illinois | 60068 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Nevada Cancer Center | Las Vegas | Nevada | 89135 | — |
| Atlantic Melanoma Center | Morristown | New Jersey | 07962 | — |
| University Of New Mexico Cancer Center | Albuquerque | New Mexico | 87131 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| St Lukes Hospital And Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Vanderbilt-Ingram Cancer Ctr | Nashville | Tennessee | 37232 | — |
| Center For Oncology Research & Treatment, P.A. | Dallas | Texas | 75230 | — |
| Huntsman Cancer Institute At The Univ. Of Utah | Salt Lake City | Utah | 84112 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 77 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00636168, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2019 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00636168 live on ClinicalTrials.gov.